NCT06644495View on ClinicalTrials.gov

Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

NSCLC

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06644495 - Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib | Biotech Hunter | Biotech Hunter